Fighting The High Cost Of Rx Drugs

AN INDUSTRY-WIDE TACTIC—At least eight of the top 10 drug makers have paid off their competition to block generics from entering the market. The FTC estimates that pay for delay deals cost consumers and taxpayers $3.5 billion every year in higher drug prices.

It's Time To End Pay For Delay

DRIVING UP THE COST OF RX DRUGS
We all know prescription drugs cost too much. That’s partly because brand-name drug companies have been paying off generic drug makers to delay competition and keep prices high. This practice, called “pay for delay,” is commonplace in the pharmaceutical industry.
 
It's anti-competitive. It's hurting consumers. And it has to stop.

WE PAY THE PRICE
Competition is known to bring drug prices down 85-90 percent:

  • 30-day supply of the cholesterol drug Lipitor costs $194. The generic equivalent? Only $16.
  • The medication needed to prevent blood costs, Plavix, costs $205, while its generic equivalent is $13 for that same 30-day supply.
  • The antibiotic Cipro, used to treat a number of infections, costs $52; the generic costs $7.

And because drug companies can use pay for delay to maintain their strangle hold on the market long after their active-ingredient patents expire, consumers who rely on these drugs for their health are often forced to pay these higher prices for years before they see the generic.

CASE STUDY: Experts expected narcolepsy drug Provigil to go generic in 2006, but pay-for-delay deals kept the generic off the market until 2012. In the meantime, many multiple sclerosis patients had to pay over $1,200 each month for the drug, or manage without it. Bad news for consumers, but good news for the drug company. As the CEO of Cephalon, the drug company that makes Provigil, said about the deal, “We got six more years of patent protection. That’s $4 billion in sales that no one expected.”

TAKING ON BIG PHARMA
Drug companies spend more on lobbying than any other industry. But if we build enough public support, we can stop the industry's pay-for-delay scheme and bring down drug and health care costs for consumers and taxpayers.

We're calling on Congress to put an end to pay for delay once and for all.

Issue updates

News Release | U.S. PIRG Education Fund | Health Care

Consumer Group Calls for Competitive Health Care Marketplaces

State policy-makers can address rising health care costs by implementing an effective health insurance exchange, according to a report released today by consumer advocacy group U.S. PIRG.

> Keep Reading
News Release | U.S. PIRG Education Fund | Health Care

New Rules on Insurance Premium Hikes Will Protect Consumers

A statement by U.S. PIRG Health Care Advocate Larry McNeely on regulations released yesterday by the U.S. Department of Health and Human Services regarding the review of unreasonable health insurance premium rate increases.

> Keep Reading
News Release | U.S. PIRG | Health Care

House Bill Would Drive Up Health Costs, Restrict Consumers' Choices

H.R. 1213 would hurt consumers by zeroing out the start-up funds needed to get new competitive state health insurance marketplaces off the ground. Delaying the establishment of these exchanges will mean years more of the status quo – a stagnant marketplace with little competition, fewer choices and unchecked premium growth.

> Keep Reading
Report | U.S. PIRG | Health Care

The Cost of Repeal for Young Adults

Before moving forward with the health care repeal, however, policy-makers must consider the real-life consequences that their policy choices would have on millions of young Americans. U.S. PIRG has examined official research, data, and projections from independent sources, to provide a detailed picture of repeal’s impact on young adults. The evidence reveals that young people would face significant costs if the Affordable Care Act is repealed.

> Keep Reading
Report | U.S. PIRG | Health Care

The Cost of Repeal

The evidence suggests that the costs of health care repeal are substantial and many of the asserted benefits of repeal do not stand up under scrutiny. But policy makers have additional options. They instead should work to implement the law properly in the states and take the steps to lower health care costs which the federal law fails to take.

> Keep Reading

Pages

Report | U.S. PIRG | Health Care

D.C. Area Consumers Pay More for Prescription Drugs While Pharmaceutical Profits Soar

A price survey of 33 pharmacies in the D.C. Area, conducted by the national consumer groups Public Citizen, U.S. PIRG and the D.C. chapter of the Gray Panthers shows that consumers who lack prescription drug coverage are being charged retail prices that are nearly double the prices prescription drug makers charge their most favored customers.

> Keep Reading

Pages

View AllRSS Feed

PRIORITY ACTION

Tell your senator that patients can't afford to wait another day. We need to end "Pay for Delay" right now.

Support Us

Your donation supports U.S. PIRG’s work to stand up for consumers on the issues that matter, especially when powerful interests are blocking progress.

Consumer Alerts

Join our network and stay up to date on our campaigns, get important consumer updates and take action on critical issues.
Optional Member Code